May 6, 2026 08:26AM
May 6, 2026 08:25AM
May 4, 2026 07:31AM
May 4, 2026 07:30AM
May 1, 2026 07:30AM
Apr 9, 2026 07:30AM
Mar 30, 2026 07:30AM InflaRx presents vilobelimab data for pyoderma gangrenosum at AAD meeting
Mar 30, 2026 07:30AM
Mar 20, 2026 04:14PM
Mar 20, 2026 06:59AM
Mar 19, 2026 07:30AM
Jan 8, 2026 08:11AM
Jan 8, 2026 08:00AM
Dec 31, 2025 06:37AM Raymond James on Inflarx NV (IFRX): 'analyses of the unblinded Phase 3 dataset for vilobelimab...suggests evidence of a positive trend'
Dec 30, 2025 07:30AM
Dec 30, 2025 07:30AM
Dec 11, 2025 07:32AM
Dec 11, 2025 07:30AM
Nov 10, 2025 07:30AM
Nov 10, 2025 07:30AM
Sep 2, 2025 06:19AM H.C. Wainwright Assumes Inflarx NV (IFRX) at Buy
Aug 7, 2025 07:30AM
May 28, 2025 04:55AM
May 28, 2025 01:30AM
May 7, 2025 07:30AM
Apr 29, 2025 06:32AM
Mar 20, 2025 07:30AM
Mar 7, 2025 08:00AM InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
Feb 28, 2025 09:00AM
Jan 16, 2025 06:54AM
Jan 15, 2025 12:30PM
Jan 15, 2025 12:30PM
Nov 15, 2024 07:52AM
Nov 15, 2024 07:51AM
Nov 8, 2024 07:30AM InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
Sep 26, 2024 06:44AM
Sep 25, 2024 07:31AM
Sep 25, 2024 07:30AM
Aug 8, 2024 07:30AM
Jul 30, 2024 07:30AM
Jun 24, 2024 08:04AM
Jun 24, 2024 08:02AM InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
Jun 5, 2024 12:00PM
Jun 5, 2024 12:00PM
May 21, 2024 02:30PM
May 21, 2024 02:30PM
May 8, 2024 07:30AM
Apr 30, 2024 07:30AM
Apr 30, 2024 07:30AM InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
Apr 24, 2024 07:30AM

322,967 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All